Pancreatic Ductal Adenocarcinoma
Conditions
Keywords
Pancreatic ductal adenocarcinoma (PDA)Neoplasms, LDE225, nab-paclitaxel, abraxane, gemcitabine, neoadjuvant, cytotoxic, hedgehog inhibitor, stromal cells, resectable PDA, Pancreatic Diseases, Carcinoma, Sonidegib
Brief summary
This is an open-label phase 1/2 study that will combine the chemotherapy agents gemcitabine and nab-paclitaxel with an oral hedgehog inhibitor LDE225 (Sonidegib). The objective is to assess tolerability and the resection rate of patients with borderline resectable pancreatic adenocarcinoma who use this treatment.
Detailed description
The investigators propose treating 6-12 patients during the phase 1 portion and 40 patients in the phase 2 stage. Phase 1 Stage: Four cycles of gemcitabine 1000 mg/m2 and nab-paclitaxel 125 mg/m2 on days 1, 8 and 15 in combination with escalating doses (400mg, or 600mg, or 800mg) of LDE-225. After completion of neoadjuvant therapy, the subjects will receive combined chemotherapy and radiation. Then subjects who are eligible for resection will go ahead with surgery. Following resection, subjects will complete two additional cycles of gemcitabine 1000 mg/m2 and nab-paclitaxel 125 mg/m2 in combination with LDE-225. Phase 2 Stage: In the Phase 2 stage the patients will be randomized to receive gemcitabine and nab-paclitaxel with or without the hedgehog inhibitor LDE225: 1. Arm A: Four cycles of gemcitabine 1000 mg/m2 and nab-paclitaxel 125 mg/m on days 1, 8 and 15 in combination with LDE-225 at the recommended phase 2 dose. 2. Arm B: Four cycles of gemcitabine 1000 mg/m2 and nab-paclitaxel 125 mg/m on days 1, 8 and 15. After completion of neoadjuvant therapy, the subjects will receive combined chemotherapy and radiation. Then subjects who are eligible for resection will go ahead with surgery. Following resection, subjects will complete two additional cycles of the pre-surgical therapy. Several correlative laboratory studies will be conducted during the course of this study. They were designed around the goals of providing us with a better understanding of how the stroma-tumor interaction and the intra-tumoral drug levels of gemcitabine are affected with the use of LDE-225. Two additional biopsies are required to participate in this study.
Interventions
DRUGLDE225-600mg
Phase I: oral LDE225 (Sonidegib), 600mg daily. Phase II Arm A: LDE225 at the recommended phase 2 dose on Days 1, 8 and 15. Cycles repeated every 28 days.
DRUGGemcitabine
Four cycles of Gemcitabine 1000 mg/m2 on days 1, 8, and 15 every 28 days.
DRUGnab-paclitaxel
Four cycles of nab-Paclitaxel 125 mg/m2 on days 1, 8, and 15 every 28 days.
DRUGLDE225-400mg
Phase I: oral LDE225 (Sonidegib), 400mg daily.
DRUGLDE225-800mg
Phase I: oral LDE225 (Sonidegib), 800mg daily.
Sponsors
Novartis Pharmaceuticals
The Skip Viragh Foundation
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Study design
Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Histologically or cytologically confirmed adenocarcinoma of the pancreas. * Must have borderline resectable pancreatic adenocarcinoma * Measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension * No previous radiotherapy, surgery, chemotherapy or investigational drug therapy. * Age \>18 years * Life expectancy of greater than 1 month. * ECOG (Eastern Cooperative Oncology Group) performance status 0 or 1 * Adequate organ and marrow function * Asymptomatic for jaundice and ascites. Pain symptoms should be stable. * Negative serum pregnancy test * Sexually active males should agree to use a barrier form of contraception, even if they have had a vasectomy, during the study and for 6 months after stopping LDE225. Males should not donate sperm during treatment, and for up to six months after last dose. Sexually active females of child bearing potential agree to using highly effective contraception during study and for 20 months after final dose of LDE225. * Agree not to donate blood products for 12 months after stopping LDE225. * Willing to have two biopsies while on treatment for correlative studies.
Exclusion criteria
* Patients who have had previous radiotherapy, surgical resection, chemotherapy or investigational drug therapy for pancreatic adenocarcinoma. * Patient has known metastatic disease. * History of allergic reactions attributed to compounds of similar chemical or biologic composition to LDE225 or other agents used in the study. * Patients taking medications with narrow therapeutic indices that are metabolized by cytochrome P450 (CYP450), including warfarin sodium (Coumadin®) * Uncontrolled illness including, but not limited to, ongoing or active infection requiring IV antibiotics, symptomatic congestive heart failure not controlled with medication, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements. * Pregnant women are excluded * Patient has undergone a major surgery, other than diagnostic surgery within four weeks prior to starting treatment on this study. * Patients who are receiving treatment with medications known to be moderate and strong inhibitors or inducers of CYP3A4/5 or drugs metabolized by CYP2B6 or CYP2C9 that have narrow therapeutic index, and that cannot be discontinued before starting treatment with LDE225. Medications that are strong CYP3A4/5 inhibitors should be discontinued at least 7 days and strong CYP3A/5 inducers for at least 2 weeks prior to starting treatment with LDE225. * Patients with neuromuscular disorders. * Patients with impaired cardiac function.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Phase I - Safety and Feasibility of Gemcitabine and Nab-Paclitaxel in Combination With LDE-225 as Neoadjuvant Therapy as Measured by Number of Participants Who Tolerated the Maximal Dose of LDE-225 | 5 years | Number of participants who tolerated the maximal dose of LDE-225 in combination with gemcitabine, nab-paclitaxel as neoadjuvant therapy in patients with borderline resectable pancreatic adenocarcinoma (PDA). |
| Phase II - Resection Rate of Two Preoperative Chemotherapy Regimens in Patients With Borderline Resectable PDA | 5 years | Number of participants with borderline resectable pancreatic adenocarcinoma (PDA) who undergo resection after therapy |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Overall Survival | 5 years | Number of months alive from cycle 1, Day 1 until 5 years post-intervention or death, whichever comes first. |
| Overall Tumor Response as Determined by Number of Participants With Complete or Partial Response | 5 years | Number of participants who experienced complete response (CR) or partial response (PR), as defined by RECIST v1.0; where CR is a disappearance of all target lesions and PR is ≥30% reduction of target lesions. |
Countries
United States
Participant flow
Recruitment details
10 subjects were screen failures. All of 13 subjects were enrolled into the Arm/group: Phase I: gem, nab-paclitaxel, and LDE225-600mg. Other Arm/group did not enroll any subjects due to early termination of the study.
Participants by arm
| Arm | Count |
|---|---|
| Phase I, Gem, Nab-paclitaxel, and LDE225-600mg Phase I:
Four cycles of Gemcitabine 1000 mg/m2 and nab-Paclitaxel 125 mg/ m2 on days 1, 8, and 15 every 28 days cycle in combination with oral LDE225 600 mg daily | 13 |
| Phase I, Gem, Nab-paclitaxel, and LDE225-400mg Phase I:
Four cycles of Gemcitabine 1000 mg/m2 and nab-Paclitaxel 125 mg/ m2 on days 1, 8, and 15 every 28 days cycle in combination with oral LDE225 400 mg daily | 0 |
| Phase I, Gem, Nab-paclitaxel, and LDE225-800mg Phase I:
Four cycles of Gemcitabine 1000 mg/m2 and nab-Paclitaxel 125 mg/ m2 on days 1, 8, and 15 every 28 days cycle in combination with oral LDE225 800 mg daily | 0 |
| Phase II, Arm A: Gem, Nab-paclitaxel, and LDE 225 Phase II:
Arm A: Four cycles of gemcitabine 1000 mg/m2 and nab-Paclitaxel 125 mg/m2 on days 1, 8 and 15 in combination with LDE-225 at the recommended phase 2 dose from Phase I. Cycles repeated every 28 days. | 0 |
| Phase II, Arm B: Gemcitabine and Nab-paclitaxel Phase II:
Arm B: Four cycles of gemcitabine 1000 mg/m2 and nab-Paclitaxel 125 mg/m2 on days 1, 8 and 15. Cycles repeated every 28 days. | 0 |
| Total | 13 |
Baseline characteristics
| Characteristic | Total | Phase I, Gem, Nab-paclitaxel, and LDE225-600mg |
|---|---|---|
| Age, Continuous | 61.62 years STANDARD_DEVIATION 9.32 | 61.62 years STANDARD_DEVIATION 9.32 |
| Race/Ethnicity, Customized Not Hispanic or Latino Black or African American | 2 Participants | 2 Participants |
| Race/Ethnicity, Customized Not Hispanic or Latino Others | 0 Participants | 0 Participants |
| Race/Ethnicity, Customized Not Hispanic or Latino White or Caucasian | 11 Participants | 11 Participants |
| Sex: Female, Male Female | 7 Participants | 7 Participants |
| Sex: Female, Male Male | 6 Participants | 6 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk | EG004 affected / at risk |
|---|---|---|---|---|---|
| deaths Total, all-cause mortality | 2 / 13 | 0 / 0 | 0 / 0 | 0 / 0 | 0 / 0 |
| other Total, other adverse events | 13 / 13 | 0 / 0 | 0 / 0 | 0 / 0 | 0 / 0 |
| serious Total, serious adverse events | 8 / 13 | 0 / 0 | 0 / 0 | 0 / 0 | 0 / 0 |
Outcome results
Primary
Phase II - Resection Rate of Two Preoperative Chemotherapy Regimens in Patients With Borderline Resectable PDA
Number of participants with borderline resectable pancreatic adenocarcinoma (PDA) who undergo resection after therapy
Time frame: 5 years
Population: No data was collected to assess this outcome measure as the study was terminated before Phase II.
Primary
Phase I - Safety and Feasibility of Gemcitabine and Nab-Paclitaxel in Combination With LDE-225 as Neoadjuvant Therapy as Measured by Number of Participants Who Tolerated the Maximal Dose of LDE-225
Number of participants who tolerated the maximal dose of LDE-225 in combination with gemcitabine, nab-paclitaxel as neoadjuvant therapy in patients with borderline resectable pancreatic adenocarcinoma (PDA).
Time frame: 5 years
Population: This measure only applies to the Phase I arms. All 13 subjects participated in the Arm/group: Phase I: gem, nab-paclitaxel, and LDE225-600mg. There were no participants enrolled in other two Arm/group as the study was terminated.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Phase I: Gem, Nab-paclitaxel, and LDE225-600mg | Phase I - Safety and Feasibility of Gemcitabine and Nab-Paclitaxel in Combination With LDE-225 as Neoadjuvant Therapy as Measured by Number of Participants Who Tolerated the Maximal Dose of LDE-225 | 13 Participants |
| Phase I: Gem, Nab-paclitaxel, and LDE225-400mg | Phase I - Safety and Feasibility of Gemcitabine and Nab-Paclitaxel in Combination With LDE-225 as Neoadjuvant Therapy as Measured by Number of Participants Who Tolerated the Maximal Dose of LDE-225 | 0 Participants |
| Phase I: Gem, Nab-paclitaxel, and LDE225-800mg | Phase I - Safety and Feasibility of Gemcitabine and Nab-Paclitaxel in Combination With LDE-225 as Neoadjuvant Therapy as Measured by Number of Participants Who Tolerated the Maximal Dose of LDE-225 | 0 Participants |
Secondary
Overall Survival
Number of months alive from cycle 1, Day 1 until 5 years post-intervention or death, whichever comes first.
Time frame: 5 years
Population: This measure only applies to the Phase I arms. All 13 subjects participated in the Arm/group: Phase I: gem, nab-paclitaxel, and LDE225-600mg. There were no participants enrolled in other two Arm/group as the study was terminated.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Phase I: Gem, Nab-paclitaxel, and LDE225-600mg | Overall Survival | 34.3 months |
Secondary
Overall Tumor Response as Determined by Number of Participants With Complete or Partial Response
Number of participants who experienced complete response (CR) or partial response (PR), as defined by RECIST v1.0; where CR is a disappearance of all target lesions and PR is ≥30% reduction of target lesions.
Time frame: 5 years
Population: This measure only applies to the Phase I arms. All 13 subjects participated in the Arm/group: Phase I: gem, nab-paclitaxel, and LDE225-600mg. There were no participants enrolled in other two Arm/group as the study was terminated.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Phase I: Gem, Nab-paclitaxel, and LDE225-600mg | Overall Tumor Response as Determined by Number of Participants With Complete or Partial Response | 3 Participants |